Core Insights - Apyx Medical Corporation has received regulatory approval for the Apyx One console and plans to launch commercial sales in South Korea, with initial orders expected in Q4 2025 [1][3] - The Apyx One console features a 3-in-1 energy system that allows for advanced surgical procedures, including Renuvion technology, and is designed for ease of use with adaptive touch screens and energy quantification [2] - The cosmetic surgery market in South Korea is projected to grow from $1.7 billion in 2024 to over $3.9 billion by 2033, indicating a significant opportunity for Apyx Medical's body contouring technology [3] Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering innovative products such as Renuvion and the AYON Body Contouring System, which provide controlled heat to tissue for surgical procedures [4] - The AYON Body Contouring System is FDA-cleared and designed to integrate multiple surgical capabilities, enhancing the versatility and precision of body contouring treatments [4]

Core Insights - Catheter Precision, Inc. has successfully secured a significant tender for its VIVO™ system at Albert Szent-Györgyi Health Centre in Hungary, marking its first installation in the country and reinforcing its growth strategy in Central and Eastern Europe [1][2][3] Company Overview - Catheter Precision is a U.S.-based medical device company focused on innovative solutions for cardiac arrhythmias, emphasizing collaboration with physicians and continuous product advancement [5] Product Details - The VIVO system is a non-invasive 3D imaging technology designed to identify the origin of ventricular arrhythmias prior to procedures, thereby streamlining workflow and reducing procedure time. It has received FDA marketing clearance and holds the CE Mark [4] Market Expansion - The tender at Szeged University Hospital is part of a broader strategy for Catheter Precision to expand into emerging markets, with Hungary identified as a key region for growth. This installation is expected to facilitate wider adoption of the VIVO system throughout Central Europe [2][3]

Core Viewpoint - DexCom, Inc. is a leading medical device company specializing in continuous glucose monitoring systems, with a market cap of $24.8 billion, indicating its significant influence in the diabetes care market [1][2]. Company Overview - DexCom designs and commercializes CGM systems, including a small implantable device for measuring glucose levels and an external receiver for data transmission [1]. - The company is categorized as a large-cap stock, reflecting its substantial market presence and dominance in the medical devices industry [2]. Market Performance - DexCom's stock has experienced a decline of 30.9% from its 52-week high of $93.25, reached on February 18, and has underperformed the S&P 500 Index, which gained 6.5% over the same period [3]. - Over the past six months, DexCom shares fell by 24.6%, and over the past year, they decreased by 18.7%, significantly lagging behind the S&P 500's gains of 15.1% and 12.9%, respectively [4]. Technical Analysis - The stock has been trading below its 200-day moving average since early August, indicating a bearish trend, although it recently traded above the 50-day moving average [4]. Challenges and Concerns - The company's underperformance is attributed to an FDA warning letter regarding manufacturing issues, trade war concerns with China affecting supply chains, and higher scrap rates along with sensor deployment issues [5]. - Management is optimistic about improvements due to new quality controls and shipping methods [5]. Financial Results - In Q3, DexCom reported an adjusted EPS of $0.61, exceeding Wall Street's expectation of $0.57, and revenue of $1.21 billion, surpassing the forecast of $1.18 billion [6]. - The company anticipates full-year revenue between $4.6 billion and $4.7 billion [6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, specifically titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to lead the case, with claims made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire Medical Systems assured investors that it had taken necessary steps for the launch of Inspire V, claiming high demand would support the rollout [5]. - Contrary to these assurances, the company allegedly failed to prepare clinicians and payors adequately, leading to significant delays and weak demand due to excess inventory of older devices [6]. - On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, attributing this to undisclosed factors including incomplete training at implanting centers and poor demand [7]. - Following this announcement, Inspire's stock price fell by $42.04 per share, a decline of more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch WorkshopCARLSBAD, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo® Technology Platform for cervical fusion surgeries. Surgeons involved in the clinical evaluation will also present early clinical data at the Cervical Spine Research Society (CSRS) 53rd Annual ...

1&h=4005353447&u=https://protect.checkpoint.com/v2/r01/___http:/www.shoulderinnovations.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo1MDg3NTIyMDRlZ (information on the website is not incorporated by reference into this presentation and should not be considered part of this document).You should not place undue reliance on forward-looking statements. The information in this press release is provided as of today's date only, and, except as required by federal securities law, the Company does not undertake to publicl ...

Core Insights - The article highlights York Water as an exceptional dividend stock with a 209-year streak of continuous payouts, significantly longer than any other company [15][12] - It emphasizes the stability and predictability of dividend-paying companies, particularly in the utility sector, which can navigate economic uncertainties effectively [4][16] Company Overview - York Water, a water and wastewater utility based in South-Central Pennsylvania, has been paying dividends since 1816, making it one of the rarest dividend stocks [13][15] - The company has a market capitalization of approximately $471 million and services 57 municipalities [13] Dividend Performance - York Water has maintained a continuous dividend payment for 209 years, a record unmatched by any other company, with only three U.S. presidents having served during its payout history [15] - The company's dividend yield is currently 2.74%, which is considered modest but reflects a significant share price appreciation of 476% since the year 2000 [21] Financial Stability - The predictability of York Water's cash flow is attributed to the stable demand for water services and the regulatory environment that protects its pricing [16][18] - The Pennsylvania Public Utility Commission (PPUC) regulates rate increases, ensuring a stable revenue stream for York Water [18] Growth Potential - York Water has requested a rate increase of $24.2 million, which would boost its annual revenue by 31% from the projected $78 million for the current year [19] - The company has also pursued bolt-on acquisitions to expand its customer base, which is expected to be accretive to its earnings [20] Valuation - York Water is currently valued at less than 21 times forward-year earnings, representing a 29% discount to its average forward price-to-earnings multiple over the past five years [20]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, of the December 29, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To join the class action, investors can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 29, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4] Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5] - Defendants allegedly overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues, leading to increased regulatory scrutiny and potential legal repercussions [5] - The lawsuit claims that the public statements made by the defendants were materially false and misleading, resulting in investor damages when the true information became public [5]

Core Viewpoint - Kestra Medical Technologies, Ltd. has announced an upsized underwritten public offering of 6,000,000 common shares priced at $23.00 per share, aiming for gross proceeds of $138 million before expenses [1]. Company Overview - Kestra Medical Technologies, Ltd. is a commercial-stage company focused on wearable medical devices and digital healthcare, specifically targeting improvements in patient outcomes for cardiovascular diseases through innovative monitoring and therapeutic technologies [6]. Offering Details - The offering is expected to close on December 4, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 900,000 common shares at the public offering price [1]. - The offering is being managed by BofA Securities, Piper Sandler, J.P. Morgan, Goldman Sachs & Co. LLC, and Wells Fargo Securities as bookrunners [2].

"十四五"期间，浙江省市县已联动向企业有针对性地选派了1700多名科研人员，涉及人工智能、生物科技等领域。目前，浙江 已拥有国家高新技术企业超4.7万家，科技成果转化体系不断完善，区域创新能力居全国前列。贯彻落实四中全会精神，眼下，浙江 正加快推动创新资源向企业集聚，促进创新链产业链资金链人才链深度融合。 0:00 / 3:34 央视网消息（新闻联播）：党的二十届四中全会提出，加快高水平科技自立自强，引领发展新质生产力。浙江、辽宁认真学习 贯彻全会精神，抢抓新一轮科技革命和产业变革历史机遇，推动教育科技人才一体改革发展，增强自主创新能力。 浙江：推动创新链产业链资金链人才链深度融合 在浙江温州的这家医疗器械企业，来自高校的科研人员正在进行新品测试。依托政府选派的科研人员，企业突破了研发难题， 开发出的新产品受到市场欢迎。"十四五"时期，浙江建立健全人才流动共享机制，通过从高校等机构选聘高层次科研人员到企业兼 职的方式，破解高校科研成果转化难与企业创新人才短缺的难题。 辽宁：增强自主创新能力 发展新质生产力 前不久，辽宁材料实验室在金属材料强化领域取得重要突破，新的研究成果能够大幅提升金属材料性能，在航空航天、 ...